Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 6/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411064 | 1.00 | CYP3A4 (0.50) | CYP3A4CASP1RECQLDDB1CRBN | |
| Hydrochloric Acid SCHEMBL25305777 | 0.98 | CYP3A4 (0.48) | CYP3A4CASP1RECQLDDB1CRBN | |
| SCHEMBL18956824 | 0.91 | HDAC4 (0.47) | CYP3A4CASP1RECQLDDB1CRBN | |
| SCHEMBL16334825 | 0.91 | HDAC4 (0.52) | CYP3A4CASP1RECQLDDB1CRBN | |
| Hydrochloric Acid SCHEMBL4444055 | 0.89 | HDAC4 (0.50) | CYP3A4CASP1RECQLDDB1CRBN | |
| SCHEMBL1176491 | 0.89 | KMO (0.53) | CYP3A4CASP1RECQLDDB1CRBN | |
| SCHEMBL6100303 | 0.89 | KMO (0.53) | CYP3A4CASP1RECQLDDB1CRBN | |
| SCHEMBL2264849 | 0.86 | HTR2C (0.62) | CYP3A4CASP1RECQLDDB1CRBN | |
| SCHEMBL29843001 | 0.86 | DHFR (0.48) | CYP3A4CASP1RECQLDDB1CRBN | |
| SCHEMBL1570447 | 0.86 | DHFR (0.48) | CYP3A4CASP1RECQLDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | claimed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | claimed |
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | claimed |
| EP-1996578-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| EP-1996558-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| WO-2008009487-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | claimed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | claimed |
| US-20260125359-A1 | HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS | FUJIAN HAIXI PHARMACEUTICALS CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4695236-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250353853-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2025-11-20 | — | — | US | disclosed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| CN-119630645-A | Flavivirus inhibitors | IRBM股份公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-4496569-A1 | CXCR6 SULFONAMIDE COMPOUNDS | ChemoCentryx, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| CN-101018784-A | Bicyclic amides as kinase inhibitors | NOVARTIS AG (CH) | 2007-08-15 | — | — | CN | disclosed |
| WO-2007076474-A1 | NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1794149-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007031265-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031265-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006059234-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | SLC8B1, MCU, GLS | CYP3A4 4544/4885CASP1 3063/4885RECQL 2225/4885 |
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | PHKG1, MAP3K20, CDK2 | CYP3A4 3642/4885CASP1 1911/4885RECQL 2876/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | CYP3A4 684/4885CASP1 4018/4885RECQL 1865/4885 |
| US-20260125359-A1 | HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS | ERBB2, ERBB3, ARRB1 | CYP3A4 3530/4885CASP1 4155/4885RECQL 4068/4885 |
| US-20250353853-A1 | FLAVIVIRUS INHIBITORS | SPINT2, EIF2AK2, DDX5 | CYP3A4 1757/4885CASP1 511/4885RECQL 702/4885 |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | MAP3K20, PHKG1, PHKG2 | CYP3A4 4140/4885CASP1 2238/4885RECQL 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.